Wall Street Analysts Are Bullish on Top Healthcare Picks


There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Nabriva (NBRV) and Cryolife (CRY) with bullish sentiments.

Nabriva (NBRV)

Northland Securities analyst Carl Byrnes maintained a Buy rating on Nabriva today and set a price target of $12.50. The company’s shares closed yesterday at $2.99.

Byrnes wrote:

“We are confident that any and all manufacturing- related issues and deficiencies relating to the one CMO facility referenced in the CRL can be remedied, supporting approval of CONTEPO. Nabriva will request a ‘Type A’ meeting with the FDA to review the FDA’s findings. Considering that the FDA is not citing concerns regarding efficacy, safety, or need for additional data, we believe CONTEPO will garner approval upon confirmation of correction of the CMO-related deficiencies. Conference Call @ 8AM EDT: Nabriva will be hosting a conference call this morning at 8AM EDT. The conference call number is (866) 811-8671 (US/ Canada) or (409) 981-0874 (international), with a passcode of 8537966. Lefamulin PDUFA In mid-February 2019, the FDA accepted the NDAs for both IV and oral formulations of Lefamulin for the treatment of community-acquired bacterial pneumonia (CABP).”

According to TipRanks.com, Byrnes is ranked 0 out of 5 stars with an average return of -7.5% and a 18.9% success rate. Byrnes covers the Healthcare sector, focusing on stocks such as Aridis Pharmaceuticals Inc, Adamas Pharmaceuticals, and Flexion Therapeutics.

Currently, the analyst consensus on Nabriva is a Moderate Buy with an average price target of $9.63.

See today’s analyst top recommended stocks >>

Cryolife (CRY)

Northland Securities analyst Suraj Kalia maintained a Buy rating on Cryolife today and set a price target of $32. The company’s shares closed yesterday at $30.66.

Kalia noted:

“We note that our EPS is GAAP and does not jibe with company guidance.”

According to TipRanks.com, Kalia is a 5-star analyst with an average return of 10.6% and a 58.6% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Varex Imaging Corporation, and Strata Skin Sciences Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cryolife with a $32 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts